ReGen Therapeutics is thought poised for new funding after announcing bullish test results for its Colostrinin Alzheimer's treatment.

AIM dog ReGen, which rekindled interest last year with test results suggesting its Zolpidem insomnia treatment could sometimes reverse some effects of severe brain damage, is now to present its latest findings on Colostrinin to the Eighth International Conference on Alzheimer's and Parkinson's Diseases at Salzburg in Austria next month. The company says an 'in vivo' study has shown Colostrinin increases the life-span and improves the neurological performance of 'inbred mice predisposed to premature ageing'.

Percy Lomax, ReGen's indefatigably cheerful executive chairman, comments 'in developing our nutraceutical product Colostrinin, we are looking to help improve people's quality of life. This study shows that, with respect to ageing and neurological functions, we may be able to do that.'

The other day Barclays Stockbrokers Gerrard emerged with six per cent of ReGen, which lost £2.2 million in 2005 and chalked up another £1.1 million deficit in the first half of last year. Shares in ReGen, floated at 20p seven years ago, have hitherto been disastrous performers, falling to 0.82p in autumn 2005 and only rallying 0.15p to 1.05p today on the latest Colostrinin findings.

The company raised £1million last July at 1p. Company watchers believe a further funding could be imminent.

Gamblers only.

ReGen Therapeutics	AIM	£0.95m	6.50p	0.00p
Click here for interactive charting
Other company articles:
ReGen product in US launch			17/10/2007
Test cheer for ReGen			23/08/2007
Alzheimer's group claims test cheer			05/02/2007
ReGen raises £1.1m			21/07/2006
Qonnectis upbeat			14/07/2006